Melanotan-1

MC1R Agonism and the cAMP → MITF → Tyrosinase Cascade#

Melanotan-1 is a linear 13-amino-acid analog of endogenous α-MSH with two substitutions — norleucine at position 4 and D-phenylalanine at position 7 — that make it roughly 1000× more resistant to enzymatic degradation and substantially more potent at the melanocortin-1 receptor (MC1R) than native α-MSH.

When MT-1 binds MC1R on epidermal melanocytes, the Gs-coupled receptor activates adenylate cyclase → ↑cAMP → PKA → phosphorylation of CREB → transcription of MITF (microphthalmia-associated transcription factor), the master regulator of melanogenesis. MITF then drives expression of tyrosinase, TRP-1, and TRP-2, the three enzymes that convert tyrosine into melanin inside melanosomes.

The practical outcome: darker skin that actually protects against UV, rather than just looking tanned.

The Pheomelanin → Eumelanin Shift#

This is the mechanism that matters for looksmaxxers running MT-1 year-round. At baseline, fair-skinned users (Fitzpatrick I–II, especially redheads with MC1R loss-of-function variants) preferentially produce pheomelanin — the reddish-yellow pigment that burns instead of tans and generates free radicals under UV.

MC1R activation flips the melanocyte toward eumelanin, the brown-black pigment that absorbs UV broadly and quenches reactive oxygen species. MT-1 forces this switch pharmacologically, which is why EPP patients on afamelanotide get clinically meaningful photoprotection without needing to get visibly dark first.

"Patients treated with afamelanotide could spend significantly longer periods in direct sunlight without pain and showed increased melanin density in skin samples." — Langendonk JG et al., New England Journal of Medicine, 2015

For the aesthetic user, this is the mechanism behind the "clean tan" MT-1 is known for — it's producing the pigment your skin would produce if you had a higher-functioning MC1R allele, not staining you an artificial orange.

UV as the Rate-Limiting Signal#

This is the mechanism most new users miss and why "users injected for three weeks and got nothing" threads exist. MC1R agonism by MT-1 primes melanocytes — upregulating the machinery — but melanin synthesis itself is still gated by a second signal: UV-induced DNA damage in keratinocytes, which releases α-MSH locally and drives melanosome transfer to surrounding skin cells.

MT-1 saturates the first signal. UV provides the second. Without UV exposure (sun or tanning bed), you get modest baseline darkening at best. With even moderate UV (10–20 min, 2–3×/week), the primed melanocytes respond dramatically faster and darker than they would without the peptide. This is why the protocol is always MT-1 + UV, never MT-1 alone.

Photoprotection Beyond Pigment#

MC1R signaling does more than make pigment. Downstream of cAMP, it also upregulates nucleotide excision repair pathways and endogenous antioxidant defenses in keratinocytes, meaning MT-1-treated skin handles UV-induced DNA damage better even at matched pigment levels. Afamelanotide also appears to produce systemic effects unrelated to skin — in EPP cohorts, erythrocyte protoporphyrin and AST dropped significantly over extended treatment.

"Our data show a sustained, clinically relevant reduction of AST and erythrocyte protoporphyrin, suggesting benefits beyond photoprotection." — Minder AE et al., Therapeutic Advances in Rare Disease, 2022

For aesthetics-focused users this translates into a plausible reduction in cumulative photoaging and actinic damage — a longevity-adjacent bonus on top of the cosmetic tan.

MC1R Selectivity: Why MT-1 Is Cleaner Than MT-2#

MT-1 and MT-2 both agonize the melanocortin family, but MT-2 is a cyclic heptapeptide with significant affinity for MC3R, MC4R, and MC5R in addition to MC1R. That promiscuity is the source of MT-2's signature side effects: MC4R activation in the CNS drives nausea, appetite suppression, and spontaneous erections; MC3R/MC5R hit a range of autonomic effects.

MT-1 is far more MC1R-selective. You still get some flushing and mild nausea in the first week (largely from transient autonomic activation that tachyphylaxes quickly), but the priapism, heavy appetite crash, and intense GI upset that drive users off MT-2 are mostly absent.

"Afamelanotide exhibits a plasma half-life of about 30–50 min following subcutaneous injection, but its pharmacodynamic effects on skin pigmentation persist for weeks." — Minder EI et al., Clinical Pharmacokinetics, 2017

That PK/PD disconnect — short plasma half-life, weeks of pigment response — is the final piece of the mechanism. You're not dosing a drug that lingers. You're pulsing a signal that triggers a biological program (melanogenesis) which then runs on its own timescale. That's why daily microdoses during loading work, why 1–2× weekly maintenance holds color, and why the tan fades over 1.5–3 months after you stop rather than dropping off with the peptide's half-life.

Common (most users)#

• Facial flushing — warm, red-face sensation starting 15–30 minutes post-injection, lasting 30–60 minutes. Tachyphylaxes within the first week. Inject at night so you sleep through it; drop to 0.25 mg if it's intolerable and titrate back up.
• Mild nausea — peaks 30–60 minutes after injection and usually resolves inside the first week of loading. Inject with food in your stomach, at night, and avoid stacking the shot right before cardio or a meal you care about. Drop the dose by half if it persists past week one.
• Injection-site reactions — minor redness, itching, or a small welt. Rotate abdominal sites, use fresh slin pins, and keep reconstituted vials properly refrigerated.
• Headache — the most common AE in the Scenesse trials. Hydrate, dose at night, consider splitting the dose across two smaller injections if it's recurrent.

"The most common adverse events were headache and implant-site reaction, with no serious drug-related adverse effects observed across clinical studies." — Barman-Aksözen & Minder, Drugs (2016)

• Darkening of existing moles, freckles, nipples, lips, and gums — expected, not pathological. Photograph your skin before starting so you have a baseline to compare against.
• Appearance of new lentigines / freckles — common in fair (Fitzpatrick I–II) skin, especially on sun-exposed areas. Track them; anything changing in shape, border, or color goes to a dermatologist.
• Decreased appetite — mild and usually welcome on a cut. Eat on schedule rather than by hunger cue to avoid unintentional undereating.

Uncommon (dose-dependent or individual)#

• Persistent nausea past week two — back off to 0.25 mg daily or every other day. If it doesn't resolve, the product may be underdosed/overdosed relative to label (sourcing issue) or you're in the minority who simply don't tolerate melanocortin agonists well.
• Fatigue / mild malaise on loading days — cut dose frequency to every other day during the load.
• Vivid dreams / disrupted sleep — shift the injection to earlier in the evening rather than right before bed.
• Blood pressure changes — minor swings reported anecdotally. If you're on-cycle with orals or already running hot BP, check cuff readings during the load.
• Spontaneous erections — much rarer than with MT-2 due to MT-1's MC1R selectivity, but possible at higher doses (1.5–2 mg+). Drop the dose; this is a signal you're overshooting what you need for pigment.
• Excessive / uneven pigmentation — patchy darkening on hands, knuckles, or old scars. Reduce frequency; pigment will even out over weeks once melanocyte turnover catches up.

Rare but serious#

• Changing moles — any nevus that changes size, shape, color, or border during a cycle. Stop dosing and see a dermatologist promptly. Don't rationalize it.
• New pigmented lesions with irregular features — same response: stop, get it checked.
• Severe allergic / hypersensitivity reaction to the peptide or vehicle — hives, swelling, breathing difficulty. Stop and seek care. Rare, but reported with any injected peptide.
• Unexplained systemic symptoms — persistent severe headache, vision changes, sustained hypertension. Stop and investigate.

The long-term safety data here is genuinely reassuring for a community peptide:

"Our data show a sustained, clinically relevant reduction of AST and erythrocyte protoporphyrin, suggesting benefits beyond photoprotection." — Minder et al., Ther Adv Rare Dis (2022)

240+ patient-years of afamelanotide exposure in the Swiss EPP cohort produced no serious drug-related AEs and trended favorably on liver enzymes — a profile most recreational compounds can't match.

Hard contraindications#

These are non-negotiable. MT-1 stimulates melanocyte activity; the theoretical risk of promoting existing transformed or dysplastic pigment cells is high enough that every serious source draws the line here.

• Personal history of melanoma — do not use. Ever.
• Dysplastic nevi / atypical mole syndrome — do not use.
• Active non-melanoma skin cancer (basal cell, squamous cell) — do not use until fully treated and cleared, and then only after dermatology review.
• Strong family history of melanoma (first-degree relatives) — do not use.
• High nevus count without a recent full-body dermatology screen — do not start until you've had one. This is the single most important pre-cycle step for MT-1.
• Pregnancy or breastfeeding — no safety data. Do not use.

Gender considerations & PCT#

MT-1 is a pigment-signaling peptide, not a hormone. It does not touch the HPTA, does not aromatize, does not affect lipids, and does not require PCT or ancillaries. Dosing is identical for men and women. Women running MT-1 should still do the same baseline mole check — the skin-cancer contraindications apply equally regardless of sex. The one female-specific note: discontinue before any planned conception, as safety in pregnancy has not been established.